IP Library Granted Patent US 9,556,494
Granted Patent B2
US 9,556,494 · App. 14/360,051 · Granted Jan 31, 2017

Methods for diagnosing human immunodeficiency virus infections

Inventors: David G. Russell (Ithaca, NY); Henry Mwandumba (Liverpool, GB); Kondwani Jambo (Liverpool, GB)
Assignees: Cornell University; Liverpool School of Tropical Medicine
C12Q1/703C12Q1/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,494
App. No.
14/360,051
Granted
Jan 31, 2017
Kind
B2
Abstract

Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion.

Claims (10)

1. A method for detecting human immunodeficiency virus (HIV) in a sample comprising:

i) providing a sample obtained from a mucosal surface present in the lungs of an individual, wherein the sample comprises macrophages;

ii) contacting the sample with a plurality of fluorescently labeled oligonucleotide probes having distinct sequences, wherein the probes are complementary to HIV mRNA; and

iii) using fluorescence in situ hybridization in combination with flow cytometry to identify macrophages as infected with HIV based on a fluorescent signal emitted from the macrophages or as not infected with HIV based on a lack of a fluorescent signal emitted from the macrophages,

wherein the plurality of fluorescently labeled oligonucleotide probes comprises 48 distinct, non-overlapping probes that are each 20-30 nucleotides in length and are complementary to HIV gp120 mRNA.

2. The method of claim 1 , wherein macrophages infected with HIV are identified, and wherein the macrophages were infected in vivo by HIV not more than eight weeks before performing step ii) and step iii).

3. The method of claim 2 , wherein the macrophages were infected in vivo not more than four weeks before performing step ii) and step iii).

4. The method of claim 3 , wherein the macrophages were infected in vivo not more than one week before performing steps ii) and steps iii).

5. The method of claim 1 , wherein the macrophages are identified as not infected with HIV.

6. The method of claim 1 , wherein the mucosal surface is present in an HIV seronegative individual.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2014
From: RUSSELL, DAVID G.
To: CORNELL UNIVERSITY
Reel/Frame 034195/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2014
From: MWANDUMBA, HENRY; JAMBO, KONDWANI
To: LIVERPOOL SCHOOL OF TROPICAL MEDICINE
Reel/Frame 034195/0506 →
CONFIRMATORY LICENSE Recorded Sep 8, 2014
From: CORNELL UNIVERSITY / CORNELL RESEARCH FOUNDATION, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033695/0934 →
Continuity (2)
Provisional Application 61563216 · Nov 23, 2011
Related Publication 20140342934A1 · Nov 20, 2014